ImmunoVaccine Inc. Stock Toronto S.E.
Equities
IMV
CA45254B1031
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- CAD | - |
|
2023 | Transcript : IMV Inc., Q4 2022 Earnings Call, Mar 16, 2023 | |
2022 | Transcript : IMV Inc., Q3 2022 Earnings Call, Nov 11, 2022 |
Sales 2021 | - | Sales 2022 | - | Capitalization | 30.6M 41.74M |
---|---|---|---|---|---|
Net income 2021 | -36M -49.1M | Net income 2022 | -38M -51.83M | EV / Sales 2021 | - |
Net cash position 2021 | 18.96M 25.86M | Net Debt 2022 | 7.67M 10.47M | EV / Sales 2022 | - |
P/E ratio 2021 |
-2.47
x | P/E ratio 2022 |
-0.53
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.93% |
Managers | Title | Age | Since |
---|---|---|---|
Andrew Hall
CEO | Chief Executive Officer | - | 20-11-09 |
Brittany Davison
DFI | Director of Finance/CFO | - | - |
Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 58 | 20-06-30 | |
Kyle Kuvalanka
BRD | Director/Board Member | 56 | 21-03-31 |
Markus Warmuth
BRD | Director/Board Member | 53 | 18-11-05 |
1st Jan change | Capi. | |
---|---|---|
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- IMVI.F Stock
- IMV Stock